Literature DB >> 12796835

Chronic dysimmune neuropathy. A subclassification based upon the clinical features of 102 patients.

Mark Busby1, Michael Donaghy.   

Abstract

The Chronic Dysimmune neuropathies (CDN) are a clinically heterogeneous group of polyneuropathies united by their presumed immune mediated aetiology. At present such neuropathies are classified as Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Multifocal Motor Neuropathy (MMN) and the Neuropathies in association with serum Paraproteins (Paraproteinaemic Neuropathies). This classification fails to recognise other distinctive syndromes and is limited by heterogeneity within, and overlap between, subgroups. We have refined this clinical subclassification by a review of a consecutive series of 102 unselected patients with CDN referred to a single neurologist. We recognise 6 clinical subtypes of CDN: one sensory ataxic group; three motor-sensory subgroups (chronic motor sensory demyelinating neuropathy, subacute motor sensory demyelinating neuropathy and a multifocal motor sensory neuropathy); and two pure motor subgroups (symmetric pure motor demyelinating neuropathy and multifocal motor neuropathy). This subclassification allows distinct syndromes to be recognised and helps resolve problems of heterogeneity and overlap. Distinction between these subgroups is of immediate practical relevance to patient management. Although steroids are beneficial for most of the subgroups, this is not so for both of the pure motor syndromes which should be treated with intravenous immunoglobulin. Patients with chronic development of Motor Sensory Demyelinating Neuropathy respond less well to steroids than those with a subacute onset. An association was found between elderly patients with Subacute Motor Sensory Demyelinating Neuropathy and carcinomas. Within any clinical subgroup patients behave similarly regardless of the presence of associated paraproteins or nerve specific antibodies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12796835     DOI: 10.1007/s00415-003-1068-2

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  7 in total

1.  Motor-dominant chronic inflammatory demyelinating polyneuropathy.

Authors:  Akio Kimura; Takeo Sakurai; Akihiro Koumura; Megumi Yamada; Yuichi Hayashi; Yuji Tanaka; Isao Hozumi; Hiide Yoshino; Tatsuhiko Yuasa; Takashi Inuzuka
Journal:  J Neurol       Date:  2009-11-22       Impact factor: 4.849

Review 2.  Epidemiology of neuroimmunological diseases.

Authors:  Peter Flachenecker
Journal:  J Neurol       Date:  2006-09       Impact factor: 4.849

Review 3.  Movement disorders and neuropathies: overlaps and mimics in clinical practice.

Authors:  Francesco Gentile; Alessandro Bertini; Alberto Priori; Tommaso Bocci
Journal:  J Neurol       Date:  2022-06-03       Impact factor: 6.682

4.  Chronic inflammatory demyelinating polyneuropathy as a possible novel component of autoimmune poly-endocrine-candidiasis-ectodermal dystrophy.

Authors:  Mariella Valenzise; Antonella Meloni; Corrado Betterle; Bruno Giometto; Massimo Autunno; Anna Mazzeo; Antonio Cao; Filippo De Luca
Journal:  Eur J Pediatr       Date:  2008-05-07       Impact factor: 3.183

Review 5.  Association between chronic inflammatory demyelinating polyneuropathy and gastrointestinal malignancies.

Authors:  Adnan Malik; Rani Berry; Brian M Fung; James H Tabibian
Journal:  Clin J Gastroenterol       Date:  2020-11-04

Review 6.  Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype.

Authors:  Emily K Mathey; Susanna B Park; Richard A C Hughes; John D Pollard; Patricia J Armati; Michael H Barnett; Bruce V Taylor; P James B Dyck; Matthew C Kiernan; Cindy S-Y Lin
Journal:  J Neurol Neurosurg Psychiatry       Date:  2015-02-12       Impact factor: 10.154

7.  Deterioration after corticosteroids in CIDP may be associated with pure focal demyelination pattern.

Authors:  Filip Eftimov; Marinus H Liesdek; Camillus Verhamme; Ivo N van Schaik
Journal:  BMC Neurol       Date:  2014-04-04       Impact factor: 2.474

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.